Rationally Designed, Nontoxic, Nonamyloidogenic Analogues of Human Islet Amyloid Polypeptide with Improved Solubility

Biochemistry

Volumn 53, Issue 37, 2014, Pages 5876-5884

  Wang, Hui ^a   Abedini, Andisheh ^b   Ruzsicska, Bela ^a   Raleigh, Daniel P ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGREGATES; CELL DEATH; CELLS; CYTOLOGY; INSULIN; PH; POLYPEPTIDES; SOLUBILITY;

AMYLOID FORMATION; CLINICAL APPLICATION; GLYCEMIC CONTROL; PANCREATIC BETA CELLS; PHYSIOLOGICAL PH; POLYPEPTIDE HORMONES; POOR SOLUBILITIES; SECOND GENERATION;

GLYCOPROTEINS;

AMYLIN; AMYLOID; HUMAN ISLET AMYLOID POLYPEPTIDE; INSULIN; PRAMLINTIDE; PROLINE; UNCLASSIFIED DRUG; PEPTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SOLUBILITY; GLYCEMIC CONTROL; GRAFT FAILURE; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MUTANT; MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PEPTIDE SYNTHESIS; PH; PRIORITY JOURNAL; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; CELL CULTURE; CHEMISTRY; HUMAN; MOLECULAR GENETICS; PROCEDURES; PROTEIN ENGINEERING; RAT; SYNTHESIS;

RATTUS;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; CELLS, CULTURED; HUMANS; HYDROGEN-ION CONCENTRATION; INSULIN; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDES; PROLINE; PROTEIN ENGINEERING; RATS;

EID: 84927558655     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi500592p     Document Type: Article

References (45)

1. Kruger, D. F. and Gloster, M. A. (2004) Pramlintide for the treatment of insulin-requiring diabetes mellitus: Rationale and review of clinical data Drugs 64, 1419 - 1432
2. Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., and Reid, K. B. (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients Proc. Natl. Acad. Sci. U.S.A. 84, 8628 - 8632
3. Clark, A., Lewis, C. E., Willis, A. C., Cooper, G. J. S., Morris, J. F., Reid, K. B. M., and Turner, R. C. (1987) Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes Lancet 2, 231 - 234
4. Gedulin, B. R., Rink, T. J., and Young, A. A. (1997) Dose-response for glucagonostatic effect of amylin in rats Metabolism 46, 67 - 70
5. Rushing, P. A., Hagan, M. M., Seeley, R. J., Lutz, T. A., D'Alessio, D. A., Air, E. L., and Woods, S. C. (2001) Inhibition of central amylin signaling increases food intake and body adiposity in rats Endocrinology 142, 5035 - 5038
6. Clementi, G., Caruso, A., Cutuli, V. M. C., deBernardis, E., Prato, A., and AmicoRoxas, M. (1996) Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat Experientia 52, 677 - 679
7. Scherbaum, W. A. (1998) The role of amylin in the physiology of glycemic control Exp. Clin. Endocrinol. Diabetes 106, 97 - 102
8. Westermark, P., Wernstedt, C., O'Brien, T. D., Hayden, D. W., and Johnson, K. H. (1987) Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone Am. J. Pathol. 127, 414 - 417
9. Clark, A., Wells, C. A., Buley, I. D., Cruickshank, J. K., Vanhegan, R. I., Matthews, D. R., Cooper, G. J., Holman, R. R., and Turner, R. C. (1988) Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes Diabetes Res. Clin. Pract. 9, 151 - 159
10. Westermark, P. and Grimeliu, L. (1973) Pancreatic-islet cells in insular amyloidosis in human diabetic and non-diabetic adults AActa Pathol., Microbiol. Immunol. Scand., Sect. A 81, 291 - 300
11. Westermark, P. and Wilander, E. (1978) The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus Diabetologia 15, 417 - 421
12. Andersson, A., Bohman, S., Borg, L. A., Paulsson, J. F., Schultz, S. W., Westermark, G. T., and Westermark, P. (2008) Amyloid deposition in transplanted human pancreatic islets: A conceivable cause of their long-term failure Exp. Diabetes Res. 2008, 562985
13. Potter, K. J., Abedini, A., Marek, P., Klimek, A. M., Butterworth, S., Driscoll, M., Baker, R., Nilsson, M. R., Warnock, G. L., Oberholzer, J., Bertera, S., Trucco, M., Korbutt, G. S., Fraser, P. E., Raleigh, D. P., and Verchere, C. B. (2010) Islet amyloid deposition limits the viability of human islet grafts but not porcine islet grafts Proc. Natl. Acad. Sci. U.S.A. 107, 4305 - 4310
14. Koda, J. E., Fineman, M., Rink, T. J., Dailey, G. E., Muchmore, D. B., and Linarelli, L. G. (1992) Amylin concentrations and glucose control Lancet 339, 1179 - 1180
15. Fineman, M. S., Giotta, M. P., Thompson, R. G., Kolterman, O. K., and Koda, J. E. (1996) Amylin response following Sustacal(R) ingestion is diminished in type II diabetic patients treated with insulin Diabetologia 39, 566
16. Kruger, D. F., Gatcomb, P. M., and Owen, S. K. (1999) Clinical implications of amylin and amylin deficiency Diabetes Educ. 25, 389 - 397
17. Westermark, P., Engstrom, U., Johnson, K. H., Westermark, G. T., and Betsholtz, C. (1990) Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation Proc. Natl. Acad. Sci. U.S.A. 87, 5036 - 5040
18. Westermark, P., Andersson, A., and Westermark, G. T. (2011) Islet amyloid polypeptide, islet amyloid, and diabetes mellitus Physiol. Rev. 91, 795 - 826
19. Abedini, A. and Raleigh, D. P. (2006) Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: Is there a critical amyloidogenic domain in human IAPP? J. Mol. Biol. 355, 274 - 281
20. Fox, A., Snollaerts, T., Errecart Casanova, C., Calciano, A., Nogaj, L. A., and Moffet, D. A. (2010) Selection for nonamyloidogenic mutants of islet amyloid polypeptide (IAPP) identifies an extended region for amyloidogenicity Biochemistry 49, 7783 - 7789
21. Abedini, A. and Raleigh, D. P. (2005) The role of His-18 in amyloid formation by human islet amyloid polypeptide Biochemistry 44, 16284 - 16291
22. Abedini, A., Meng, F. L., and Raleigh, D. P. (2007) A single-point mutation converts the highly amyloidogenic human islet amyloid polypeptide into a potent fibrillization inhibitor J. Am. Chem. Soc. 129, 11300 - 11301
23. Chakraborty, S., Mukherjee, B., and Basu, S. (2013) Pinpointing proline substitution to be responsible for the loss of amyloidogenesis in IAPP Chem. Biol. Drug Des. 82, 446 - 452
24. Buchanan, L. E., Dunkelberger, E. B., Tran, H. Q., Cheng, P. N., Chiu, C. C., Cao, P., Raleigh, D. P., de Pablo, J. J., Nowick, J. S., and Zanni, M. T. (2013) Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet Proc. Natl. Acad. Sci. U.S.A. 110, 19285 - 19290
25. Cao, P., Meng, F., Abedini, A., and Raleigh, D. P. (2010) The ability of rodent islet amyloid polypeptide to inhibit amyloid formation by human islet amyloid polypeptide has important implications for the mechanism of amyloid formation and the design of inhibitors Biochemistry 49, 872 - 881
26. Weyer, C., Maggs, D. G., Young, A. A., and Kolterman, O. G. (2001) Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control Curr. Pharm. Des. 7, 1353 - 1373
27. Fineman, M., Weyer, C., Maggs, D. G., Strobel, S., and Kolterman, O. G. (2002) The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus Horm. Metab. Res. 34, 504 - 508
28. Fineman, M. S., Koda, J. E., Shen, L. Z., Strobel, S. A., Maggs, D. G., Weyer, C., and Kolterman, O. G. (2002) The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type I diabetes Metabolism 51, 636 - 641
29. Kleppinger, E. L. and Vivian, E. M. (2003) Pramlintide for the treatment of diabetes mellitus Ann. Pharmacother. 37, 1082 - 1089
30. Schmitz, O. and Brock, B. (2004) Amylin agonists: A novel approach in the treatment of diabetes Diabetes 53, S233 - S238
31. Seth, R., Terry, D. E., Parrish, B., Bhatt, R., and Overton, J. M. (2012) Amylin-leptin coadministration stimulates central histaminergic signaling in rats Brain Res. 1442, 15 - 24
32. Trevaskis, J. L., Lei, C., Koda, J. E., Weyer, C., Parkes, D. G., and Roth, J. D. (2010) Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats Obesity 18, 21 - 26
33. Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., and Baron, A. D. (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies Proc. Natl. Acad. Sci. U.S.A. 105, 7257 - 7262
34. Abedini, A. and Raleigh, D. P. (2005) Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP, a highly amyloidogenic and aggregation-prone polypeptide Org. Lett. 7, 693 - 696
35. Marek, P., Woys, A. M., Sutton, K., Zanni, M. T., and Raleigh, D. P. (2010) Efficient microwave-assisted synthesis of human islet amyloid polypeptide designed to facilitate the specific incorporation of labeled amino acids Org. Lett. 12, 4848 - 4851
36. Abedini, A., Singh, G., and Raleigh, D. P. (2006) Recovery and purification of highly aggregation-prone disulfide-containing peptides: Application to islet amyloid polypeptide Anal. Biochem. 351, 181 - 186
37. Tu, L.-H., Serrano, A. L., Zanni, M. T., and Raleigh, D. P. (2014) Mutational analysis of preamyloid intermediates: The role of His-Tyr interactions in islet amyloid formation Biophys. J. 106, 1520 - 1527
38. Jha, S., Snell, J. M., Sheftic, S. R., Patil, S. M., Daniels, S. B., Kolling, F. W., and Alexandrescu, A. T. (2014) pH dependence of amylin fibrillization Biochemistry 53, 300 - 310
39. Charge, S. B. P., Dekoning, E. J. P., and Clark, A. (1995) Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in-vitro Biochemistry 34, 14588 - 14593
40. Meng, F. L., Raleigh, D. P., and Abedini, A. (2010) Combination of kinetically selected inhibitors in trans leads to highly effective inhibition of amyloid formation J. Am. Chem. Soc. 132, 14340 - 14342
41. Moriarty, D. F. and Raleigh, D. P. (1999) Effects of sequential proline substitutions on amyloid formation by human amylin20-29 Biochemistry 38, 1811 - 1818
42. Meng, F. L., Marek, P., Potter, K. J., Verchere, C. B., and Raleigh, D. P. (2008) Rifampicin does not prevent amyloid fibril formation by human islet amyloid polypeptide but does inhibit fibril thioflavin-T interactions: Implications for mechanistic studies of β-cell death Biochemistry 47, 6016 - 6024
43. Cao, P., Tu, L. H., Abedini, A., Levsh, O., Akter, R., Patsalo, V., Schmidt, A. M., and Raleigh, D. P. (2012) Sensitivity of amyloid formation by human islet amyloid polypeptide to mutations at residue 20 J. Mol. Biol. 421, 282 - 295
44. Yan, L.-M., Velkova, A., Tatarek-Nossol, M., Rammes, G., Sibaev, A., Andreetto, E., Kracklauer, M., Bakou, M., Malideli, E., Göke, B., Schirra, J., Storr, M., and Kapurniotu, A. (2013) Selectively N-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and Aβ40 Angew. Chem., Int. Ed. 52, 10378 - 10383
45. Yan, L.-M., Tatarek-Nossol, M., Velkova, A., Kazantzis, A., and Kapurniotu, A. (2006) Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis Proc. Natl. Acad. Sci. U.S.A. 103, 2046 - 2051